{"name":"William Wiley, MD","slug":"william-wiley-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Dexamethasone ophthalmic insert 0.4 mg","genericName":"Dexamethasone ophthalmic insert 0.4 mg","slug":"dexamethasone-ophthalmic-insert-0-4-mg","indication":"Other","status":"marketed"},{"name":"Topical Prednisolone Acetate Ophthalmic Drops","genericName":"Topical Prednisolone Acetate Ophthalmic Drops","slug":"topical-prednisolone-acetate-ophthalmic-drops","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Dexamethasone ophthalmic insert 0.4 mg","genericName":"Dexamethasone ophthalmic insert 0.4 mg","slug":"dexamethasone-ophthalmic-insert-0-4-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Topical Prednisolone Acetate Ophthalmic Drops","genericName":"Topical Prednisolone Acetate Ophthalmic Drops","slug":"topical-prednisolone-acetate-ophthalmic-drops","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTFBOc284aHEzZGJDSmJJYko3aG5WbXRmV0lmTkUtOWU1WlBsZnF5ZVpJVjRxRjI2N0FqTnRobFZISE1GbDh0ZXNZMTlqSFNDSWZJY0Fjd2hNNXR5SUlhZnFQMmFrV1Q3MFVqUVBFYnBUWEhBZ2pMV3ppTUdR?oc=5","date":"2024-11-25","type":"trial","source":"Wiley","summary":"Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia - Wiley","headline":"Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNeTV6ZmFCcTk0ZnpUYmpjMVFqTlZJaEZaUkhLN3ZZcjh1eWdTWjlReVhGNnVSME1SSnNRX0V3NjZ5bVFZakVXay1aRFhSaXphdkxYOXA3WUExcl8zUDZISS1TT1VfbHI3X181Q3VZLVd2aVdVempWa1l0UkNFdXc4VjZYQlh6RDc4TzFKaUNobWlFUXBSYm1FRVVIX05oNDBDUnNfU3lWZ19laUhVX1V0VTRrMHNscXZOT0ttSHJB?oc=5","date":"2024-03-20","type":"regulatory","source":"Healio","summary":"Wiley Chambers, MD, retires from FDA, will serve as ophthalmic consultant - Healio","headline":"Wiley Chambers, MD, retires from FDA, will serve as ophthalmic consultant","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE1xOUVyXy1CNnJqdDJKYnVjb1ZEZ3FCRFFXTVFKdWpUcVMzRHNiWXVheGhUb1NnQ3MtS0kwc0hpUUNRR1NNWGk1Mmw5dU1ENlhXb2s1Mi04bm4xTDV2cjNBUHFOVkE3UndqMFJvRVh4ZElqUG96?oc=5","date":"2024-01-01","type":"patent","source":"Wiley","summary":"Generic cancer drugs are still in short supply - Nelson - 2024 - Cancer Cytopathology - Wiley","headline":"Generic cancer drugs are still in short supply - Nelson - 2024 - Cancer Cytopathology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE91V0QxMkhnSFFna3lwYk01UTk2VHdBVnlfZGhMaUU1d3M4UmN4cDNBcFN0MnNoZmRJZVl5VmgwcU01dmRUZkRyeUdOV1B6V1pZM0tQeG9FX1p4RmRmYWZUMDg4U0FnYWZaM2ZBWWJkSW5QeGVrOE53V1lyYw?oc=5","date":"2020-11-06","type":"pipeline","source":"Wiley","summary":"First person profile: William Sellers, MD - Wiley","headline":"First person profile: William Sellers, MD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxNR0RfT1RZODJEMlFUUWRPQ3FwbGh0eTJZRGRsNHBOYVFCclRQU3RVOHRMa0k5TE4wUDdfUjhxa0ZDaEQzTy1kYTBMalhCODZlN0JMOHcxQkVQMjBScTlMRkR6MktBRkEyR0EzZlBnT3RZbVVrLWRmQmlqTThCVWNub01NenI0UXNVdTFnQWwtVHdWcmFIUE1CWlRTTUlfSnBRczdKUDc2QjhFbV90cDBkRlZUSEhMckxHSnA3QTB0NThmem9uT0FfR1gyU29CSUpTYUpjYjVB?oc=5","date":"2020-09-17","type":"regulatory","source":"Healio","summary":"Ophthalmic organizations request FDA reconsider moxifloxacin removal from 503B bulk list - Healio","headline":"Ophthalmic organizations request FDA reconsider moxifloxacin removal from 503B bulk list","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgJBVV95cUxPLTFqai1jUnJMUEFTVVI0YWFuWmprWFZWNENJdnpIdi1iQ1FIWjh1bExVdVpySDZqYUZieWNyWkhaNllhZHFzVGNFNGFKZUhGVHlCcThCQmFvZ3Q2NHFMVXhvTm1SRFF4Wnpxa205Rl9QS25EZDFVVkQ0UmxmZDR6VEJncG9ITEVzRERoSF94T0I5MEllUV9wV29XX0JocTFKWF9LdEZRY0FzZWwtUzg4NmdYN25JMHBrY0FFY29BV1hyMm1lbzYzcmVPZEhYUHhCYklZclNLaE83UEtwSDlhYTJIY2diX0ZwZ2pHLUI3Q2Z3ZXN2U2E3cUpoTHl4TVBHcTAzUWEtTEJ5Yy1fZldPbDFiMWcxOWF2czV2RUJ6ZC1vMUZOaEc2cXMyX3FpcFF4anFNMVRPU3ctTnRscXc?oc=5","date":"2015-02-03","type":"pipeline","source":"PR Newswire","summary":"Imprimis Pharmaceuticals and Cleveland Eye Clinic Announce Positive Findings of Evaluation of LessDrops™ Combination Eye Drop Formulations Following LASIK Surgery - PR Newswire","headline":"Imprimis Pharmaceuticals and Cleveland Eye Clinic Announce Positive Findings of Evaluation of LessDrops™ Combination Eye","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}